Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer

References

• Lamarca A, Edeline J, McNamara MG, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;1–8. Online ahead of print.
   Web of Science ®Google Scholar
• Nagino M. Fifty-year history of biliary surgery. Ann Gastroenterol Surg. 2019;3(6):598–605.
   PubMed Web of Science ®Google Scholar
• Matsukuma S, Tokumitsu Y, Shindo Y, et al. Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg. 2019;3(4):378–389.
   PubMed Web of Science ®Google Scholar
• Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258(1):129–140.
   PubMed Web of Science ®Google Scholar
• Ishihara S, Horiguchi A, Miyakawa S, et al. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016;23(3):149–157.
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Kokudo N, Matsuyama Y, et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the liver cancer study group of Japan. Cancer. 2016;122(1):61–70.
   PubMed Web of Science ®Google Scholar
• Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–1695.
   PubMed Web of Science ®Google Scholar
• Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15(1):564.
   PubMed Web of Science ®Google Scholar
• Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection (AdBTC-1). [cited 2021 March 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03779035
   Google Scholar
• Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer. [cited 2021 March 28]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04401709
   Google Scholar
• Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147–156.
   PubMed Web of Science ®Google Scholar
• Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192–202.
   PubMed Web of Science ®Google Scholar
• Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized Phase III study. J Clin Oncol. 2019;37(8):658–667.
   PubMed Web of Science ®Google Scholar
• Primrose JN, Fox RP, Palmer DH, et al., Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20(5): 663–673. 2019.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–1027.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical practice guidelines in oncology: hepatobiliary cancers version 1. 2021
   Google Scholar
• Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1). [cited 2021 March 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02170090
   Google Scholar
• Malka D, Edeline J. Adjuvant capecitabine in biliary tract cancer: a standard option? Lancet Oncol. 2019;20(5):606–608.
   PubMed Web of Science ®Google Scholar
• Nakachi K, Konishi M, Ikeda M, et al. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan clinical oncology group study (JCOG1202, ASCOT). Jpn J Clin Oncol. 2018;48(4):392–395.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–1940.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Nagano H, Tomokuni A, et al. a prospective, randomized Phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208): kansai Hepato-Biliary oncology group. Ann Surg. 2019;270(2):230–237.
   PubMed Web of Science ®Google Scholar
• Seita K, Ebata T, Mizuno T, et al. Phase 2 trial of adjuvant chemotherapy with S - 1 for node-positive biliary tract cancer (N-SOG 09). Ann Surg Oncol. 2020;27(7):2348–2356.
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015;33(24):2617–2622.
   PubMed Web of Science ®Google Scholar
• Miura F, Yamamoto M, Gotoh M, et al. Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of the national clinical database of Japan: part 1 - Hepatectomy of more than one segment. J Hepatobiliary Pancreat Sci. 2016;23(6):313–323.
   PubMed Web of Science ®Google Scholar
• Kimura W, Miyata H, Gotoh M, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg. 2014;259(4):773–780.
   PubMed Web of Science ®Google Scholar
• Kenjo A, Miyata H, Gotoh M, et al. Risk stratification of 7,732 hepatectomy cases in 2011 from the national clinical database for Japan. J Am Coll Surg. 2014;218(3):412–422.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–277.
   PubMed Web of Science ®Google Scholar
• Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer. 2009;101(6):908–915.
   PubMed Web of Science ®Google Scholar
• Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–257. .
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
   PubMed Web of Science ®Google Scholar
• To G, Wo B, Us B, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/CALGP/ACO- GAIN-trial. BMC Cancer. 2020;20(1):122.
   PubMed Web of Science ®Google Scholar
• JCOG1920: A phase III trial of neoadjuvant Gemcitabine + Cisplatin + S-1 (GCS) vs. surgery first for resectable biliary tract cancer (NABICAT). [cited 2021 March 28]. Available from: https://jrct.niph.go.jp/en-latest-detail/jRCTs031200388
   Google Scholar
• Katayose Y, Rikiyama T, Motoi F, et al. Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study). Hepatogastroenterology. 2011;58(112):1866–1872.
   PubMedGoogle Scholar
• Katayose Y, Nakagawa K, Yoshida H, et al. Neoadjuvant chemoradiation therapy for cholangiocarcinoma to improve R0 resection rate: the first report of phase II study. J clin oncol. 2015;33(3_suppl):402.
   Web of Science ®Google Scholar
• Kobayashi S, Tomokuni A, Gotoh K, et al. Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer. Cancer Chemother Pharmacol. 2015;76(6):1191–1198.
   PubMed Web of Science ®Google Scholar
• McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 1997;174(6):605–608. discussion 608-609.
   PubMed Web of Science ®Google Scholar
• Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73(1):148–153.
   PubMed Web of Science ®Google Scholar
• Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018;105(7):839–847.
   PubMed Web of Science ®Google Scholar
• Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22(Suppl 3):S1093–1099.
   PubMed Web of Science ®Google Scholar
• Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20(1):318–324.
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Shima Y, Okabayashi T, et al. chemoradiotherapy for initially unresectable locally advanced Cholangiocarcinoma. World J Surg. 2018;42(9):2910–2918.
   PubMed Web of Science ®Google Scholar
• Hand F, Hoti E. Contemporary role of liver transplantation for the treatment of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2020;14(6):475–481.
   PubMed Web of Science ®Google Scholar
• Cambridge WA, Fairfield C, Powell JJ, et al. Meta-analysis and Meta-regression of survival after liver transplantation for unresectable Perihilar Cholangiocarcinoma. Ann Surg. 2021;273(2):240–250.
   PubMed Web of Science ®Google Scholar
• Moris D, Kostakis ID, Machairas N, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis. PLoS One. 2019;14(7):e0220527.
   PubMed Web of Science ®Google Scholar
• Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma (TRANSPHIL). [cited 2021 March 28]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02232932
   Google Scholar
• Nara S, Esaki M, Ban D, et al. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. Jpn J Clin Oncol. 2020;50(12):1353–1363.
   PubMed Web of Science ®Google Scholar
• Sakai D, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol. 2018;29(suppl_8):205.
   Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers: a Phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–830.
   PubMed Web of Science ®Google Scholar
• Jakubowski CD, Azad NS. Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). Chin Clin Oncol. 2020;9(1):2.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185.
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588.
   PubMed Web of Science ®Google Scholar
• DiPeri TP, Javle MM, Meric-Bernstam F. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol. 2021;1–4. 10.1080/17474124.2021.1896967
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Jarnagin WR. Biliary tract: is there a role for neoadjuvant and adjuvant therapy in biliary cancer? Nat Rev Gastroenterol Hepatol. 2012;9(11):622–623. .
   PubMed Web of Science ®Google Scholar
• Projected Cancer Statistics, 2020. [cited 2021 March 28]. Available from: https://ganjoho.jp/en/public/statistics/short_pred.html
   Google Scholar
• Global Burden of Disease CancerCollaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–1768.
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950–1958.
   PubMed Web of Science ®Google Scholar
• Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28–v37.
   PubMed Web of Science ®Google Scholar
• Randomized Phase II study of adjuvant chemotherapy with gemcitabine plus cisplatin versus gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy(KHBO1901). [cited 2021 March 28]. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041509
   Google Scholar
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers. [cited 2021 March 28]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03768414
   Google Scholar
• Rizzo A, Ricci AD, Tavolari S, et al. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteomics. 2020;17(5):441–452.
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–1765.
   PubMed Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–621.
   PubMed Web of Science ®Google Scholar